Chimeric MHC class I– and II–restricted non-self epitopes broaden antitumor T cell reactions
Journal of Experimental Medicine · 02.02.2026 · 223 (2)
DOI: 10.1084/jem.20250025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 05.12.2025. Verfasst von Rongsheng Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto…. Hauptthemen laut MEDLINE: Histocompatibility Antigens Class I, Histocompatibility Antigens Class II, Neoplasms, Epitopes, T-Lymphocyte. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Yanai Fund, Meiji Holdings Co., Ltd.
Abstract (Originalsprache)
The mechanism by which one non-self antigen augments T cell immune responses to another remains unclear. We found that these expanded immune responses could derive from chimeric non-self peptides. These peptides, which we termed complete T cell antigens (CTAs), must be expressed intracellularly as single-chain chimeras containing both MHC class I– and II–restricted epitopes. CTAs, even unrelated to tumor antigens, when administered as live cell adjuvants or in cDNA-transfected muscle, increased T cell reactivity against tumor neoantigens. Mechanistically, CTA treatment altered dendritic cell phenotype in a CD4+ T cell–dependent manner, suppressing CD8+ T cell exhaustion and generating self-renewing CD8+ T cells in tumors. Cancers predicted to have long non-self peptides resulting from frameshift mutations, which frequently contain CTAs, were associated with a better prognosis or benefit from PD-1 blockade therapy in mouse models and cancer patients. These findings indicate that a subset of cancer cells expressing CTAs is sufficient to evoke overall antitumor immunity by broadening T cell responses to other neoantigens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Human Genetics, McGill University, Montréal, Canada.
- Rosalind and Morris Goodman Cancer Institute, McGill University , Montréal, Canada.
- Department of Biochemistry, McGill University, Montréal, Canada.
- Research Institute of the McGill University Health Centre , Montréal, Canada.
- Faculty of Science and Engineering, Kindai University , Osaka, Japan.
ORCID-Profile: Rongsheng Zhang, Rong Ma, Merrin M L Leong, Ian R Watson, Kei Iida, Tomonori Yaguchi, Fumihiko Matsuda, Tasuku Honjo, Kenji Chamoto
Förderung
- Japan Society for the Promotion of Science
- Yanai Fund
- Meiji Holdings Co., Ltd
- Meiji Seika Pharma
- Chugai Foundation for Innovative Drug Discovery Science
- Kyoto University
Zitieren
APA
Zhang, R., Ma, R., Leong, M. M. L., Watson, I. R., Iida, K., Yaguchi, T., Matsuda, F., Honjo, T., & Chamoto, K. (2026). Chimeric MHC class I– and II–restricted non-self epitopes broaden antitumor T cell reactions. Journal of Experimental Medicine, 223(2). https://doi.org/10.1084/jem.20250025
Vancouver
Zhang R, Ma R, Leong MML, Watson IR, Iida K, Yaguchi T, et al. Chimeric MHC class I– and II–restricted non-self epitopes broaden antitumor T cell reactions. Journal of Experimental Medicine. 2026;223(2). doi:10.1084/jem.20250025
BibTeX
@article{Zhang2026,
author = {Zhang, Rongsheng and Ma, Rong and Leong, Merrin M L and Watson, Ian R and Iida, Kei and Yaguchi, Tomonori and Matsuda, Fumihiko and Honjo, Tasuku and Chamoto, Kenji},
title = {Chimeric MHC class I– and II–restricted non-self epitopes broaden antitumor T cell reactions},
journal = {Journal of Experimental Medicine},
year = {2026},
volume = {223},
number = {2},
doi = {10.1084/jem.20250025}
}
EUVIMED